Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...
LLY PE Ratio (Forward) data by YCharts. Given the popularity of GLP-1 drugs and the potential for an oral GLP-1 drug launch in 2026, Lilly remains very well positioned. As such, I think the stock ...
Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...
Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...
Niestety, wygląda na to, że Telewizja Polska nie miała tego w planach. Wielkimi krokami zbliża się tegoroczny Konkurs Piosenki Eurowizji. Tym razem słynne widowisko muzyczne odbędzie się w ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results